C4 Therapeutics, Inc. (CCCC) earnings
CCCC earnings moved a median of -2.80% by the close. Quarterly and annual CCCC reports and results, each read against the price at its own news timestamp. Back to the CCCC overview →
21 measured CCCC earnings events.
Where these CCCC earnings landedvs 21 measured CCCC earnings reactions
| Middle 50% of CCCC earnings reactions | -5.56% to +1.28% |
|---|---|
| Median reaction (to close) | -2.80% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 CCCC earnings events with a measured close landed between -5.56% and +1.28%; 43% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Press release | -4.04% | +0.78% | |
| Form 10-Q C4 Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -4.04% | +0.78% | |
| C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Press release | +0.16% | +2.92% | |
| Form 10-Q C4 Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.16% | +2.92% | |
| Form 10-K C4 Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -2.45% | -2.80% | |
| C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Press release | +0.00% | +1.28% | |
| Form 10-Q C4 Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +1.28% | |
| C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | Press release | +0.75% | +29.00% | |
| Form 10-Q C4 Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.75% | +29.00% | |
| C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | Press release | -3.85% | -3.85% | |
| Form 10-Q C4 Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -3.85% | -3.85% | |
| Form 10-K C4 Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.38% | -1.14% | |
| C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Press release | -4.58% | -6.16% | |
| Form 10-Q C4 Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -4.58% | -6.16% | |
| C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | Press release | +0.14% | -3.05% | |
| Form 10-Q C4 Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.14% | -3.05% | |
| C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | Press release | -1.17% | -5.56% | |
| Form 10-Q C4 Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -1.17% | -5.56% | |
| Form 10-K C4 Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +1.66% | +21.38% | |
| C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights | Press release | -4.94% | -18.52% | |
| Form 10-Q C4 Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -4.94% | -18.52% |
Keep exploring
More CCCC: analyst actions → · SEC filings → · CCCC overview →